[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020005167A - Metodo para el tratamiento de enfermedades gastrointestinales con tradipitant. - Google Patents

Metodo para el tratamiento de enfermedades gastrointestinales con tradipitant.

Info

Publication number
MX2020005167A
MX2020005167A MX2020005167A MX2020005167A MX2020005167A MX 2020005167 A MX2020005167 A MX 2020005167A MX 2020005167 A MX2020005167 A MX 2020005167A MX 2020005167 A MX2020005167 A MX 2020005167A MX 2020005167 A MX2020005167 A MX 2020005167A
Authority
MX
Mexico
Prior art keywords
treatment
tradipitant
gastrointestinal diseases
gastric motility
disclosed
Prior art date
Application number
MX2020005167A
Other languages
English (en)
Inventor
Mihael H Polymeropoulos
Gunther Birznieks
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2020005167A publication Critical patent/MX2020005167A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe un método para tratar trastornos de motilidad gástrica y para mejorar la motilidad gástrica, que comprende el tratamiento con el antagonista del receptor NK-1, t radipitant.
MX2020005167A 2017-11-17 2018-11-16 Metodo para el tratamiento de enfermedades gastrointestinales con tradipitant. MX2020005167A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762587681P 2017-11-17 2017-11-17
PCT/US2018/061593 WO2019099883A1 (en) 2017-11-17 2018-11-16 Method of treatment of gastrointestinal diseases with tradipitant

Publications (1)

Publication Number Publication Date
MX2020005167A true MX2020005167A (es) 2020-08-20

Family

ID=64734107

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005167A MX2020005167A (es) 2017-11-17 2018-11-16 Metodo para el tratamiento de enfermedades gastrointestinales con tradipitant.

Country Status (13)

Country Link
US (4) US20200030307A1 (es)
EP (1) EP3710000A1 (es)
JP (1) JP7306614B2 (es)
KR (1) KR20200088346A (es)
CN (1) CN111343981A (es)
AU (1) AU2018367623B2 (es)
BR (1) BR112020009520A2 (es)
CA (1) CA3081582A1 (es)
CL (1) CL2020001290A1 (es)
IL (1) IL274541B2 (es)
MX (1) MX2020005167A (es)
NZ (1) NZ764107A (es)
WO (1) WO2019099883A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210228555A1 (en) * 2018-06-08 2021-07-29 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
EP3856338B1 (en) * 2018-09-28 2024-11-06 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
EP3890735A1 (en) * 2018-12-03 2021-10-13 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US20230145932A1 (en) 2020-03-26 2023-05-11 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2024138040A1 (en) 2022-12-21 2024-06-27 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE384053T1 (de) 2002-04-26 2008-02-15 Lilly Co Eli Triazolderivate als tachykininrezeptor- antagonisten
ATE462700T1 (de) * 2003-10-24 2010-04-15 Lilly Co Eli Neue kristalline formen von ä2-ä1-(3,5- bistrifluormethylbenzyl)-5-pyridin-4-yl-1h-ä1,2 3üütriazol-4-ylü-pyridin-3-ylü-(2- chlorphenyl)methanon
CA2671770C (en) 2006-12-20 2015-09-15 Eli Lilly And Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
CN106421793B (zh) * 2009-11-18 2023-06-16 赫尔森保健股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法
EP3265087B1 (en) * 2015-03-04 2020-07-22 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
EA201891472A1 (ru) 2015-12-22 2018-12-28 Такеда Фармасьютикал Компани Лимитед Тройные модуляторы эндосомальных рецепторов, сопряженных с g-белком

Also Published As

Publication number Publication date
AU2018367623B2 (en) 2024-03-28
US20230390269A1 (en) 2023-12-07
KR20200088346A (ko) 2020-07-22
US20200030307A1 (en) 2020-01-30
EP3710000A1 (en) 2020-09-23
RU2020119259A (ru) 2021-12-17
IL274541B2 (en) 2024-10-01
JP7306614B2 (ja) 2023-07-11
IL274541B1 (en) 2024-06-01
JP2021503480A (ja) 2021-02-12
US20210330656A1 (en) 2021-10-28
CA3081582A1 (en) 2019-05-23
CN111343981A (zh) 2020-06-26
CL2020001290A1 (es) 2020-11-13
WO2019099883A1 (en) 2019-05-23
US20210093621A1 (en) 2021-04-01
IL274541A (en) 2020-06-30
BR112020009520A2 (pt) 2020-11-03
NZ764107A (en) 2024-07-05
AU2018367623A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
NZ764107A (en) Method of treatment of gastrointestinal diseases with tradipitant
EP3596156A4 (en) POLYAMIDES AND METHOD OF MANUFACTURING THEREOF
MX2020004073A (es) Procesos de siembra en serie y usos de los mismos.
HK1257120A1 (zh) 肌肉電刺激裝置
EP3237057A4 (en) Devices, systems and methods for treating urological and gastrointestinal disorders by electrical stimulation of the foot
IL269082A (en) Methods for treating lysosomal disorders
EP3723840A4 (en) SLEEVE DEPLOYMENT DEVICES FOR NERVES
CA185523S (en) Muscle stimulator
MX2022007801A (es) Formas polimorficas de rad1901-2hcl.
IL262747A (en) Anti-kv1.3 antibodies, methods for their production and use
MX2020011668A (es) Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
IL281736A (en) Methods for treating myeloproliferative diseases
EP3897641C0 (en) TREATMENT OF MOVEMENT DISORDERS
SG11202009985WA (en) Deep link authentication
IL270900A (en) Treatment of skin disorders
IL270362B (en) Glaucoma treatment
PL3858453T3 (pl) Flokulant anionowy, sposób wytwarzania flokulantu anionowego i sposób uzdatniania
IL281589A (en) Methods for treating myeloproliferative diseases
EP3775293C0 (en) TREATMENT OF LEATHER INCLUDING THE APPLICATION OF PECTIN
IL271933A (en) A method for classification and correlation between the pathological condition of the skin and the treatment and the theory of the dosage of the corresponding drugs
WO2018229796A3 (en) PROCESS FOR THE PREPARATION OF BETRIXABAN CHLORHYDRATE AND BETRIXABAN MALEATE SALT
EP3658217A4 (en) TREATMENT OF EYE DISORDERS
PT3401440T (pt) Método para produzir um pavimento luminescente, um agregado luminescente lacado e a utilização deste agregado
GB201701479D0 (en) Method of producing PEDOT.PSS based electrodes